CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin.

Cardiooncology · 2021 · PMC8111996 · PMID 33975650

Europe PMC DOI

hedged sentences

0.0001

closest p · 0.0× alpha

0.0560

boldest claim

The sentences

highly significantp < 0.0001actually significant

Association of DOX-induced cardiotoxicity with CBR3 V244M genotype status We compared left ventricular systolic function from pre- and post-DOX treatment echocardiograms in each CBR3 V244M genotype group and found a highly significant effect of DOX treatment on left ventricular systolic function (F[1,89] = 50.33, p < 0.0001, two-way ANOVA).

also in 132,142 other papers

a positive trendp = 0.056so close (0.05 < p ≤ 0.1)

In a nested case-control pilot study of patients enrolled in the Childhood Cancer Survivor Study, we identified a positive trend between CBR3 V244M genotype status and risk for anthracycline-related heart failure (odds ratio (OR) = 8.16 and p = 0.056 for GG vs.

also in 11,005 other papers

did not reach statistical significanceno p-value reported

AA (− 2.66 ml/m 2 , 95% CI [− 8.44, 3.11], p = 0.518, one-way ANOVA) which did not reach statistical significance (Fig. 2 b).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.